Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8300MR)

This product GTTS-WQ8300MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8300MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7670MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ3197MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ4297MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ13918MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ11834MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ4487MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ6382MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ14718MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW